These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

833 related articles for article (PubMed ID: 10068176)

  • 21. Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.
    Elsner F; Zeppetella G; Porta-Sales J; Tagarro I
    Clin Drug Investig; 2011; 31(9):605-18. PubMed ID: 21819159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral transmucosal fentanyl citrate for cancer breakthrough pain: a review.
    Gordon DB
    Oncol Nurs Forum; 2006 Nov; 33(2):257-64. PubMed ID: 16518441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.
    Mercadante S
    Expert Opin Pharmacother; 2012 Apr; 13(6):873-8. PubMed ID: 22424558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
    Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
    Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of oral transmucosal fentanyl citrate for prehospital pain control on the battlefield.
    Wedmore IS; Kotwal RS; McManus JG; Pennardt A; Talbot TS; Fowler M; McGhee L
    J Trauma Acute Care Surg; 2012 Dec; 73(6 Suppl 5):S490-5. PubMed ID: 23192075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain.
    Shimoyama N; Gomyo I; Teramoto O; Kojima K; Higuchi H; Yukitoshi N; Ohta E; Shimoyama M
    Jpn J Clin Oncol; 2015 Feb; 45(2):189-96. PubMed ID: 25378647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of transdermal fentanyl and oral transmucosal fentanyl citrate in the treatment of opioid naive patients with severe chronic noncancer pain.
    Collado F; Torres LM
    J Opioid Manag; 2008; 4(2):111-5. PubMed ID: 18557168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Dose-finding for treatment with a transdermal fentanyl patch : Titration with oral transmucosal fentanyl citrate and morphine sulfate].
    Mücke M; Conrad R; Marinova M; Cuhls H; Elsner F; Rolke R; Radbruch L
    Schmerz; 2016 Dec; 30(6):560-567. PubMed ID: 27072143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study.
    Parikh N; Goskonda V; Chavan A; Dillaha L
    Clin Ther; 2013 Mar; 35(3):236-43. PubMed ID: 23497761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial.
    Mystakidou K; Befon S; Kouskouni E; Gerolymatos K; Georgaki S; Tsilika E; Vlahos L
    Anticancer Res; 2001; 21(3C):2225-30. PubMed ID: 11501851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
    Rauck R; Reynolds L; Geach J; Bull J; Stearns L; Scherlis M; Parikh N; Dillaha L
    Curr Med Res Opin; 2012 May; 28(5):859-70. PubMed ID: 22480131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
    Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
    Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study.
    Portenoy RK; Messina J; Xie F; Peppin J
    Curr Med Res Opin; 2007 Jan; 23(1):223-33. PubMed ID: 17207304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial.
    Shimoyama N; Gomyo I; Katakami N; Okada M; Yukitoshi N; Ohta E; Shimoyama M
    Int J Clin Oncol; 2015 Feb; 20(1):198-206. PubMed ID: 24839047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinically important changes in acute pain outcome measures: a validation study.
    Farrar JT; Berlin JA; Strom BL
    J Pain Symptom Manage; 2003 May; 25(5):406-11. PubMed ID: 12727037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Oral transmucosal fentanyl citrate for the treatment of breakthrough pain. Results of a non-interventional study (NIS)].
    Zarth R; Ehmer M; Sittig HB
    Schmerz; 2007 Nov; 21(6):545-52. PubMed ID: 17899213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
    Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A
    Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy, safety, and tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
    Hashemi M; Zali A; Golmakani E; Delshad MH; Shadnoush M; Akbari ME
    Daru; 2021 Jun; 29(1):51-59. PubMed ID: 33475984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of oral transmucosal fentanyl citrate: potent, rapid and noninvasive opioid analgesia.
    Fine PG; Streisand JB
    J Palliat Med; 1998; 1(1):55-63. PubMed ID: 15859872
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Various formulations of oral transmucosal fentanyl for breakthrough cancer pain: an indirect mixed treatment comparison meta-analysis.
    Jandhyala R; Fullarton J
    BMJ Support Palliat Care; 2012 Jun; 2(2):156-62. PubMed ID: 24654058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.